Navigation Links
Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
Date:4/21/2009

BEIJING, April 21 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading distributor of plant and animal nutrient products located in the People's Republic of China, today announced preliminary financial results for its fiscal quarter ended March 31, 2009. The Company expects net revenue for the quarter ended March 31, 2009 to be from $12.0 million to $12.5 million, up approximately 26% to 31% from $9.5 million for the quarter ended March 31, 2008. Net income is expected to be $2.75 million to $3.0 million, up approximately 145% to 168% from the corresponding previous quarter, and fully diluted EPS on weighted average number of shares is expected to be $0.13 to $0.15.

Yongye sold over 95,000 units of its plant nutrient product in the quarter ended March 31, 2009, a 26% increase from 75,596 units sold in the corresponding period in 2008. This increase in units sold was due primarily to expansion of the distribution network, and a strong performance by the distributors who develop and maintain the independently owned, branded store network through which Yongye sells its plant product.

"Yongye has already reached significant performance milestones in 2009. Strong demand for our 'Shengmingsu' products and further expansion of our distribution network led to noteworthy revenue and profit growth," commented Mr. Zishen Wu, Chief Executive Officer of Yongye. "While strong seasonality is apparent in our quarterly sales figures, we are pleased with the financial growth which we achieved this last quarter. We also added four new provinces to our branded retail store sales trial program through which we add stores to our sales network. We are confident that we will achieve our fiscal year 2009 revenue guidance estimate of $66 million and net income guidance estimate of $15.8 million."

The Company's preliminary expectation
'/>"/>

SOURCE Yongye Biotechnology International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
2. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
3. Yongye Biotechnology International Retains CCG Investor Relations
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Announces Second Quarter Results
6. Yongye Biotechnology International Raises $9.4 Million in Private Placement
7. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
8. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
9. Yongye Biotechnology Announces Record Third Quarter Results
10. Yongye Biotechnology to Present at Roth Conference
11. Yongye Biotechnology International to Expand its Network of Branded Stores

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...c. 1 GeoVax Labs, Inc. ...lanta-based, biopharmaceutical company developing ... Immunodeficiency Virus) and other infectious agen.... ,, "Today is the 21st World AIDS Day and as w... with the HIV/AIDS pandemic, we remain focused and...
(Date:12/1/2009)... California waste-to-energy firm claims first plac...ation, smallest footprint, salable pure gas, bypro... (PRWEB) December 15, 2009 -- The fi...ve organic waste-to-energy process will take place...ry. , , ,This biowaste process known as VRAD©...
(Date:11/30/2009)...Minn., Nov. 30 Acuo Technologies, ...ement software, data migration tools and services,... and Clinics for a new Vendor Neutral Archive (VNA...s the Allina network of hospitals, clinics and aff...the Acuo Technologies DICOM Services Grid(TM) Soft...
(Date:11/30/2009)...30 Dr. Jessica Torrente, Assistant...rsity Medical Center in Washington, D.C., demonstr...mma Imaging (BSGI) in clinical practice as an adju...ancer today at the annual meeting of the Radiologi...rpose of the exhibit was to demonstrate how BSGI i...
Breaking Biology Technology:GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 2GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 3GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 4GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 5GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 6First Public Showing of Innovative Waste-to-Energy Process 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2
...TC-NCI-AACR Symposium --, SEATTLE and GENEVA, Oct...q: DNDN ) today presented preclinical data on its...ets Trp-p8 (a,transmembrane cation channel protein...rapeutic cancer target., The poster, titled, "Pre...Cancer/ Benign Prostate Hyperplasia Target," was p...
...United,Therapeutics Corporation (Nasdaq: UTHR ) a... quarter financial results before market open on,T...ill host a half-hour teleconference on Thursday,Oc...econference is,accessible by dialing 1-800-603-177...29. A rebroadcast of the teleconference will be av...
...rGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical comp...novel cancer therapies, today presented data on MP...nal posters, at the 20th,EORTC-NCI-AACR Symposium ...Geneva, Switzerland. MP-470, an orally bio-availab...d encouraging tumor regression results in,the firs...
Other Biology Technology:Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist 2Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist 3SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy 2SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy 3SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy 4
(Date:12/1/2009)...ty cancer researchers have developed a tumor-atta...blocks the growth of new tumor blood vessels. , ... cancer cells oncolytic viruses might be more ef...so carry a gene for a protein that inhibits blood-...n, is normally produced in the brain. In this stud...
(Date:12/1/2009)...cks by sharks can be solved with a new technique t...ey put on their victims, according to a University...method analogous to analyzing human fingerprints, ...omparing shark bites to the jaws and teeth of the ...of the International Shark Attack File, which is h...
(Date:12/1/2009)...able mystery, and it is a question which has conti...owering plants evolve and how did they come to dom...gy Letters reveals the evolutionary trigger which...petitive advantage over rival species, leading to ..., by Dr Tim Brodribb and Dr Taylor Field of the U...
Breaking Biology News(10 mins):Tumor-attacking virus strikes with 'one-two punch' 2New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3How did flowering plants evolve to dominate Earth? 2Palatin Technologies Inc to Raise 243 1 Million in Registered Direct Offering 13531 1Palatin Technologies Inc to Raise 243 1 Million in Registered Direct Offering 13531 2Palatin Technologies Inc to Raise 243 1 Million in Registered Direct Offering 13531 3New insights into limb formation 9549 1New insights into limb formation 9549 2Ohio KePRO Awarded Medicare Beneficiary Protection Program Support Contract 54354 1Ohio KePRO Awarded Medicare Beneficiary Protection Program Support Contract 54354 2Ohio KePRO Awarded Medicare Beneficiary Protection Program Support Contract 54354 3
...n University, Glassboro, N.J.; the University of P...ity may lead to better diagnosis of early-stage Al...stitutes of Health’s National Institute on Aging s...hree years, they determined early Alzheimer’s coul...ting electroencephalogram (EEG) signals. The study...
...opsin, the light-sensitive protein found in many m...t of Energy,s Lawrence Berkeley National Laborator...at Berkeley have demonstrated that when the abilit...d with proteorhodopsin will switch to solar power ...arch shows that proteorhodopsin contributes to a b...
...eart problems when mothers carry particular antibo... to an abstract presented by Yale School of Medici...edicine Conference February 9 in San Francisco. ,...ore birth and impairs the heart,s electrical signa...ries a 20 percent death rate and nearly all surviv...
Other Biology News:Study shows hope for early diagnosis of Alzheimer's 2Study shows hope for early diagnosis of Alzheimer's 3Study shows hope for early diagnosis of Alzheimer's 4Shedding new light on proteorhodopsin 2Shedding new light on proteorhodopsin 3
Rabbit Anti-Human NIRF Polyclonal Antibody, Unconjugated from Abcam
Alu I from New England Biolabs
Rabbit Anti-ZNF261 Polyclonal Antibody, Unconjugated from Abcam
SexA I from New England Biolabs
Biology Products: